Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Lancet Oncol. 2019 Jun 26;20(8):1098–1108. doi: 10.1016/S1470-2045(19)30329-8

Figure 3.

Figure 3.

(A) In the hospital cohort, the 5-year survival rates of the younger age group (YAG) and USPSTF group were 22% (95% CI, 17–27) vs. 23% (95% CI, 21–25), respectively. The 5-year survival rate in the YAG was not better than that in the USPSTF group (p=0·78). (B) In the community cohort, the 5-year survival rates of the YAG and USPSTF group were 16% (95% CI, 5–33) vs. 23% (95% CI, 18–28), respectively. The 5-year survival rate in the YAG was not better than that in the USPSTF group (p=0·57). The results of multivariable Cox proportional hazard models of patients meeting USPSTF screening criteria vs. YAG were presented in (C) the hospital cohort and (D) the community cohort.